Drug & intervention

empagliflozin 25 MG

RxCUI 1545665

Clinical trials32
Recruiting10
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

32 shown
SGLT2i, Pioglitazone, and Ketone Production in T2DNCT07053319 · 2026-05-11
RECRUITING
SGLT2i, Ketoacidosis, Volume Contraction, and InsulinopeniaNCT07053306 · 2025-04-29
RECRUITING
SGLT2i, Hepatic Glucose Production, and SNSNCT07053293 · 2025-01-07
RECRUITING
Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal DiseaseNCT06249932 · 2024-03-13
RECRUITING
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal DiseaseNCT06249945 · 2024-03-05
RECRUITING
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes MellitusNCT06095492 · 2023-10-30
RECRUITING
SGLTi, Hepatic Glucose Production and KetogenesisNCT05960656 · 2023-10-05
RECRUITING
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial FunctionNCT05972564 · 2023-09-06
RECRUITING
Adipose Tissue Heterogeneity and Its Link to Type 2 DiabetesNCT05501483 · 2023-02-08
RECRUITING
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research PlanNCT05057806 · 2021-01-13
RECRUITING
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy AdultsNCT06578676 · 2024-06-20
UNKNOWN
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of HyperglycemiaNCT06187285 · 2024-01-01
COMPLETED
Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes MellitusNCT06098625 · 2023-11-10
UNKNOWN
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney DiseaseNCT05373004 · 2023-03-01
UNKNOWN
Empagliflozin in Acute Heart FailureNCT05305495 · 2022-12-22
COMPLETED
Empagliflozin in Treatment of Peripheral Diabetic NeuropathyNCT05977465 · 2022-01-20
COMPLETED
SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity PilotNCT04907214 · 2021-07-29
COMPLETED
SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)NCT05037695 · 2021-07-21
UNKNOWN
Follow-up of NAFLD Patients With MRI-PDFFNCT04910178 · 2020-12-01
COMPLETED
SGLT2 Inhibition: Uric Acid Excretion StudyNCT05210517 · 2020-10-01
COMPLETED
POST-CABGDM: Empagliflozin in Perioperative CABGNCT04523064 · 2020-09-22
COMPLETED
Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two DiabetesNCT05109949 · 2020-03-30
UNKNOWN
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 DiabetesNCT04203927 · 2020-02-01
UNKNOWN
Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKDNCT04215445 · 2019-12-01
UNKNOWN
Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and AlbuminuriaNCT04061200 · 2019-11-01
UNKNOWN
Effect of Empagliflozin on Ventricular Repolarization.NCT04117763 · 2019-10-04
COMPLETED
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart FailureNCT04049045 · 2019-09-29
COMPLETED
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon SecretionNCT04061473 · 2019-04-02
COMPLETED
Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory AnginaNCT04143321 · 2018-09-10
COMPLETED
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based TherapyNCT05103306 · 2017-01-01
UNKNOWN
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RANCT02589626 · 2015-10-29
COMPLETED
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes MellitusNCT02489968 · 2015-05-12
COMPLETED

Conditions being studied

Type 2 Diabetes8Diabetes Mellitus, Type 26Diabetes Mellitus4Acute Kidney Injury2Chronic Kidney Diseases2Coronary Artery Disease2End Stage Renal Disease on Dialysis2Heart Failure With Preserved Ejection Fraction2Kidney Transplant; Complications2Obesity2Type2 Diabetes2Acute Decompensated Heart Failure1Acute Heart Failure1Arrythmia, Cardiac1Coronary Artery Bypass Surgery1Coronary Heart Disease1Diabetes After Total Pancreatectomy1Diabetes Mellitus Type 2 Without Complication1Diabetes Type 21Diabetic Nephropathy Type 21

Leading sponsors

The University of Texas Health Science Center at San Antonio5Medanta, The Medicity, India3Boehringer Ingelheim2National Taiwan University Hospital2University of Sao Paulo General Hospital2Vanderbilt University Medical Center2Amsterdam UMC, location VUmc1Asmaa Abdelfattah Elsayed1Centro Universitario de Ciencias de la Salud, Mexico1Christian Schulze1Chungbuk National University Hospital1Hyundai Pharm1Isfahan University of Medical Sciences1Karolinska Institutet1McGill University Health Centre/Research Institute of the McGill University Health Centre1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.